- Home
- RNW vs PTGX Comparison
RNW vs PTGX Comparison
Compare RNW & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNW
- PTGX
- Stock Information
- Founded
- RNW 2011
- PTGX 2006
- Country
- RNW United Kingdom
- PTGX United States
- Employees
- RNW N/A
- PTGX N/A
- Industry
- RNW Electric Utilities: Central
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- RNW Utilities
- PTGX Health Care
- Exchange
- RNW Nasdaq
- PTGX Nasdaq
- Market Cap
- RNW 2.4B
- PTGX 3.3B
- IPO Year
- RNW N/A
- PTGX 2016
- Fundamental
- Price
- RNW $7.65
- PTGX $51.25
- Analyst Decision
- RNW Strong Buy
- PTGX Strong Buy
- Analyst Count
- RNW 1
- PTGX 9
- Target Price
- RNW $7.50
- PTGX $67.11
- AVG Volume (30 Days)
- RNW 1.2M
- PTGX 1.0M
- Earning Date
- RNW 06-16-2025
- PTGX 08-05-2025
- Dividend Yield
- RNW N/A
- PTGX N/A
- EPS Growth
- RNW 16.07
- PTGX N/A
- EPS
- RNW 0.13
- PTGX 0.86
- Revenue
- RNW $1,135,947,896.00
- PTGX $207,801,000.00
- Revenue This Year
- RNW N/A
- PTGX N/A
- Revenue Next Year
- RNW $17.72
- PTGX $47.15
- P/E Ratio
- RNW $60.63
- PTGX $59.19
- Revenue Growth
- RNW 19.36
- PTGX N/A
- 52 Week Low
- RNW $5.15
- PTGX $32.50
- 52 Week High
- RNW $7.67
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- RNW 71.41
- PTGX 45.80
- Support Level
- RNW $6.72
- PTGX $49.86
- Resistance Level
- RNW $6.94
- PTGX $57.24
- Average True Range (ATR)
- RNW 0.21
- PTGX 2.06
- MACD
- RNW 0.05
- PTGX -0.78
- Stochastic Oscillator
- RNW 100.00
- PTGX 16.14
About RNW ReNew Energy Global plc
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.